Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 393

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 393
---
 by TuHURA of any representation letters and/or other similar factual support letters in connection with                         
 the documenting and supporting the tax treatment of the Mergers as a “reorganization” within the meaning of Section 368(a) of the Code; |

| • |     | receipt by TuHURA of written resignations in forms reasonably satisfactory to TuHURA, dated as of the Closing                                                                                         
 Date and effective as of the Closing executed by the officers and directors of the Company and its subsidiaries who are not to continue as officers or directors of the Company or such subsidiaries; |

| • |     | since the Signing Date, no Material Adverse Effect will have occurred that is continuing; |

| • |     | the Concurrent Investment shall have been completed and the receipt of gross proceeds to TuHURA of not less than                                   
 $20,000,000, which gross proceeds shall have been received by TuHURA, or will be received by TuHURA substantially simultaneously with the Closing; |

| • |     | the Company and (i) each holder of a Kineta Stock Option shall enter into an Optionholder Treatment                                                                                                                                           
 Agreement and (ii) holders of each of the 2023 Company Warrants not automatically exercised or canceled pursuant to their terms immediately prior to the Effective Time of the Mergers, shall enter into a Warrantholder Treatment Agreement; |

| • |     | the Estimated Net Working Capital Deficit, if any, shall not exceed $6,000,000. |

| • |     | All of the members of the Kineta Board of Directors and Kineta’s executive officers including each of their                                                       
 affiliates which hold shares of Kineta Common Stock shall have executed and delivered lock-up agreements restricting the transfer, subject to certain exceptions, 
 one-third of the shares of Kineta Common Stock received in the Initial Share Consideration; and                                                                   |

| • |     | As of immediately prior to the Effective Time, the Company and its subsidiaries will have Program Assets, cash,                                                                                      
 cash equivalents, and prepaid expenses (and for the avoidance of doubt, will not have any material assets that are not Program Assets (“Non-VISTA Assets” ) and the completion of the disposition or 
 dissolution of Kineta Chronic Pain, LLC, a Washington limited liability company and Yumanity, Inc., a Delaware corporation, will have occurred.                                                      |

249

In addition, under the Merger Agreement, the obligation of Kineta to effect the Mergers and otherwise complete the transactions contemplated by the